谷歌浏览器插件
订阅小程序
在清言上使用
VIPCreated with Sketch.

Neoadjuvant Vidutolimod and Nivolumab in High-Risk Resectable Melanoma: A Prospective Phase II Trial

Diwakar Davar,Robert M. Morrison,Amiran K. Dzutsev,Arivarasan Karunamurthy,Joe-Marc Chauvin, Florent Amatore,Julie S. Deutsch,Rodrigo X. Das Neves,Richard R. Rodrigues,John A. McCulloch,Hong Wang,Douglas J. Hartman,Jonathan H. Badger,Miriam R. Fernandes,Yulong Bai,Jie Sun,Alicia M. Cole, Poonam Aggarwal, Jennifer R. Fang,Christopher Deitrick,Riyue Bao,Umamaheswar Duvvuri,Shaum S. Sridharan,Seungwon W. Kim,Haroon A. Choudry,Matthew P. Holtzman,James F. Pingpank, James Patrick O'Toole,Richelle DeBlasio, Yang Jin,Quanquan Ding,Wentao Gao, Christopher Groetsch,Ornella Pagliano,Amy Rose, Corey Urban,Jagjit Singh,Prajan Divarkar,David Mauro,Dmitri Bobilev,James Wooldridge,Arthur M. Krieg,Matthew G. Fury,Jeffrey R. Whiteaker,Lei Zhao,Amanda G. Paulovich,Yana G. Najjar,Jason J. Luke,John M. Kirkwood,Janis M. Taube,Hyun Jung Park,Giorgio Trinchieri,Hassane M. Zarour

CANCER CELL（2024）

引用 1|浏览21
关键词
neoadjuvant,immunotherapy,ICI,PD-1,melanoma,TLR9,vidutolimod,innate agonist,macrophage,pDC
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要